Clinical Trials Browser

Phase 2 × Lymphoma, Non-Hodgkin × Bendamustine Hydrochloride × Clear all

NCT04217317 2025-05-02

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Phase 2 Terminated

6 enrolled 13 charts

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

NCT04792489 2025-04-24

DALY II USA/ MB-CART2019.1 for DLBCL

Phase 2 Recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Lymphoma, Mantle-Cell

NCT03311126 2024-10-24

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Phase 2 Terminated

21 enrolled 17 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT01754857 2023-06-27

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

Phase 2 Completed

36 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04155840 2022-04-11

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Terminated

1 enrolled 6 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00901927 2020-04-03

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

Phase 2 Terminated

14 enrolled 10 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT01133158 2018-11-01

R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial

Phase 2 Completed

61 enrolled 8 charts

Lymphoma, Non-Hodgkin

NCT01294579 2018-08-09

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

Phase 2 Completed

49 enrolled 13 charts

Lymphoma, Non-Hodgkin, Recurrence

NCT03315520 2018-05-22

BeEAC-1

Phase 2 Unknown

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT01929265 2017-10-13

IIL INFL09

Phase 2 Completed

Lymphoma, Non-Hodgkin

NCT01466153 2017-05-31

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

183 enrolled 17 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01110135 2017-05-24

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Phase 2 Completed

43 enrolled 5 charts

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01029730 2016-08-19

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

Phase 2 Completed

55 enrolled 7 charts

Lymphoma, Lymphoma, Non-Hodgkin

NCT02836639 2016-07-19

BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma

Phase 2 Unknown

Lymphoma, Non-Hodgkin

NCT00547534 2015-08-06

BVR

Phase 2 Completed

31 enrolled 9 charts

Lymphoma, Non-Hodgkin, Recurrence

NCT00069758 2014-05-09

Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

Phase 2 Completed

Lymphoma, Lymphoma, Non-Hodgkin

NCT00076349 2014-05-09

SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Phase 2 Completed

Lymphoma, Non-Hodgkin

NCT01118845 2013-07-04

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Completed

63 enrolled 46 charts

LymphoidSarcoma

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT01108341 2012-08-28

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

Phase 2 Completed

50 enrolled 10 charts

Lymphoma, Non-Hodgkin

NCT01125787 2011-07-20

Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

Phase 2 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT01131247 2011-07-20

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT00612183 2010-07-22

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Phase 2 Completed

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT00385125 2006-10-06

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Phase 2 Unknown

Lymphoma, Non-Hodgkin, Recurrence